Therapeutic strategies, targeting EGFR, have greatly improved the progression-free survival (PFS) and overall survival (OS) of the patients with NSCLC, especially in the non-smoking females with lung adenocarcinoma and 80% EGFR mutation rate [3–7]. The gene discussed is EGFR; the disease is lung adenocarcinoma.